Metastatic Renal Cell Cancer —Systemic Therapy
AbstractManagement of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year t o>2 years in mRCC.
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | India Health | Kidney Cancer | Renal Cell Carcinoma